Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis

Purpose: The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial ca...

Bibliografske podrobnosti
Main Authors:	Renata Rodrigues da Cunha Colombo Bonadio, Renata Gondim Meira Velame Azevedo, Guilherme Harada, Samantha Cabral Severino da Costa, Vanessa Costa Miranda, Daniela de Freitas, Elias Abdo Filho, Patricia Alves de Oliveira Ferreira, Flavia Gabrielli, Maria Del Pilar Estevez Diz
Format:	Article
Jezik:	English
Izdano:	American Society of Clinical Oncology 2018-01-01
Serija:	Journal of Global Oncology
Online dostop:	http://ascopubs.org/doi/10.1200/JGO.17.00146

Podobne knjige/članki

A Prospective Study of Adjuvant Radiotherapy Concomitant with Cisplatin Followed by Paclitaxel-Carboplatin in High Risk Early Stage Endometrial Cancer
od: Tarek Kamel, et al.
Izdano: (2016-12-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
od: Hamid Attarian, et al.
Izdano: (2009-07-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
od: Hamid Attarian, et al.
Izdano: (2009-09-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
od: Katsurada N, et al.
Izdano: (2020-02-01)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
od: Renata Colombo Bonadio, et al.
Izdano: (2021-12-01)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
od: Xiangbin Tan, et al.
Izdano: (2023-09-01)

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
od: Mohammad Mobayed, et al.
Izdano: (2009-11-01)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
od: Maojin You, et al.
Izdano: (2023-09-01)

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials
od: Francisco Cezar Aquino de Moraes, et al.
Izdano: (2023-11-01)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
od: Ahmed Gamal Elsayed, et al.
Izdano: (2017-08-01)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
od: Zhenhua Du, et al.
Izdano: (2015-07-01)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
od: Unedo H Markus, et al.
Izdano: (2015-04-01)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
od: Yin Tao, et al.
Izdano: (2022-03-01)

Adjuvant radiotherapy for stage I endometrial cancer.
od: Kong, A, et al.
Izdano: (2012)

Adjuvant radiotherapy for stage I endometrial cancer.
od: Kong, A, et al.
Izdano: (2012)

Analysis of the toxicity induced by carboplatin and paclitaxel regimen in ovarian cancer patients
od: Thaís A. GOUVÊA, et al.
Izdano: (2022-09-01)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
od: Maria Rubinstein, et al.
Izdano: (2019-05-01)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
od: S B Dessai, et al.
Izdano: (2016-01-01)

Evaluation of retinal nerve fibre layer and macular thickness pre-and post-chemotherapy with carboplatin and paclitaxel in patients with endometrial and ovarian cancer
od: Juen, Chin Ju
Izdano: (2021)

Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial
od: Bouke J. Koeneman, et al.
Izdano: (2024-02-01)

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy
od: Melek Kandemir, et al.
Izdano: (2015-12-01)

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
od: Lucia B Jilaveanu, et al.
Izdano: (2013-01-01)

Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?
od: Anase S. Asom, et al.
Izdano: (2022-02-01)

Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings
od: Frigerio Luigi, et al.
Izdano: (2006-07-01)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
od: Renata Rodrigues da Cunha Colombo Bonadio, et al.
Izdano: (2018-08-01)

LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma
od: Lingye Fan, et al.
Izdano: (2023-07-01)

Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals <i>CSF3</i> as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens
od: Pritsana Raungrut, et al.
Izdano: (2024-12-01)

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel
od: Chryssoula Papageorgiou, et al.
Izdano: (2023-01-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
od: Go Makimoto, et al.
Izdano: (2014-01-01)

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
od: Fountzilas Georgios, et al.
Izdano: (2006-09-01)

Recurrence Pattern after Adjuvant Radiotherapy for Endometrioid Type Endometrial Cancer
od: Yasin Durmus, et al.
Izdano: (2018-08-01)

Results of a phase I–II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer
od: Silvia C. Formenti, et al.
Izdano: (2017-03-01)

Borderline ovarian tumors: a review of its biology, molecular profile, and management
od: Renata Colombo Bonadio, et al.
Izdano: (2024-03-01)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
od: Shinya Sakata, et al.
Izdano: (2015-01-01)

Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer
od: TAN Shufen, YANG Xielan, YANG Linlin, LI Shuqing
Izdano: (2023-12-01)

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports
od: Špela Šuler Baglama, et al.
Izdano: (2022-12-01)

Everolimus plus anastrozole for female adnexal tumor of probable Wolffian origin (FATWO) with STK11 mutation
od: Maria de Pilar Estevez-Diz, et al.
Izdano: (2021-08-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
od: Tomoyuki Araya, et al.
Izdano: (2020-12-01)

Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis.
od: Kong, A, et al.
Izdano: (2007)

Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer?
od: Hung-Chuan Yu, et al.
Izdano: (2004-06-01)